ArisGlobal Announces Continued Growth with New Global Offices
Organization Opens New Offices in Belgium and Ireland
STAMFORD, CT—JUNE 25, 2012—ArisGlobal, a provider of solutions to the life science industry, announced the opening of two new offices in Antwerp, Belgium and Dublin, Ireland.
These new offices will allow the company to continue its growth and expansion in several product areas including pharmacovigilance and risk management, clinical data management and operations, regulatory affairs, and medical information management.
“We continue to grow with the addition of new customers and the development of new products and offerings. This expansion has created the need for an even broader global presence and new space in several regions of the world,” commented Vice President of European Operations, Simon Sparkes. “This expansion will help us to deliver added value to our customers and further execute on our vision of a suite of integrated life science software and services meeting the diverse needs of organizations around the world.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ifinatamab Deruxtecan Shows High Response Rates for Heavily Pretreated Small Cell Lung Cancer
September 9th 2024Potential first-in-class B7-H3 directed antibody drug conjugate ifinatamab deruxtecan shows potential to improve outcomes for patients living with difficult-to-treat form of lung cancer.
